Lyndsey A Reich Selected Research

Bexarotene (LGD1069)

2/2023	The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice.
1/2022	The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer.
1/2021	Potential therapeutic uses of rexinoids.
12/2020	The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
1/2019	Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lyndsey A Reich Research Topics

Disease

6	Neoplasms (Cancer) 02/2023 - 01/2017
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2022 - 01/2019
2	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2019
1	Inflammation (Inflammations) 12/2020
1	Hypertriglyceridemia 12/2020
1	Triple Negative Breast Neoplasms 01/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2017

Drug/Important Bio-Agent (IBA)

5	Bexarotene (LGD1069)FDA Link 02/2023 - 01/2019
4	Retinoid X Receptors (Retinoid X Receptor)IBA 02/2023 - 01/2019
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 02/2023 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
1	RNA (Ribonucleic Acid)IBA 02/2023
1	LigandsIBA 01/2022
1	LG 268IBA 01/2019
1	AntibodiesIBA 01/2019
1	LG 100268IBA 01/2019
1	Cancer VaccinesIBA 01/2017
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2017
1	TG4010IBA 01/2017
1	VaccinesIBA 01/2017

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2017
1	Immunomodulation 01/2021
1	Radiotherapy 01/2017
1	Injections 01/2017